Clinical Trial Update: Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression [Phase 2]

View source ↗

Summary

Phase 2 trial update of vismodegib in advanced gastric adenocarcinoma with SMO overexpression completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Stomach Neoplasms

Drugs mentioned

• Vismodegib (Vismodegib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Stomach Neoplasms | Phase 2 | Status: COMPLETED